Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Cash from Operations (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Cash from Operations data on record, last reported at 23754000.0 in Q4 2025.

  • For Q4 2025, Cash from Operations rose 67.61% year-over-year to 23754000.0; the TTM value through Dec 2025 reached 276391000.0, down 18.97%, while the annual FY2025 figure was 276391000.0, 18.97% down from the prior year.
  • Cash from Operations reached 23754000.0 in Q4 2025 per VRDN's latest filing, up from 84611000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 11539000.0 in Q1 2021 and bottomed at 92653000.0 in Q1 2025.
  • Average Cash from Operations over 5 years is 42064950.0, with a median of 38491500.0 recorded in 2023.
  • Peak YoY movement for Cash from Operations: tumbled 194.52% in 2023, then soared 67.61% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 16535000.0 in 2021, then plummeted by 105.88% to 34042000.0 in 2022, then dropped by 11.63% to 38000000.0 in 2023, then tumbled by 92.98% to 73332000.0 in 2024, then skyrocketed by 67.61% to 23754000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 23754000.0 in Q4 2025, 84611000.0 in Q3 2025, and 75373000.0 in Q2 2025.